ライフサイエンスコーパス: insulin action

1 s proliferation is not required for enhanced insulin action.

2 oviding a novel target for the modulation of insulin action.

3 mpairs GSIS in HF-fed mice without affecting insulin action.

4 nto lipoproteins may improve skeletal muscle insulin action.

5 -cells in islets of Langerhans, and improves insulin action.

6 nadir, or mean of the normal periodicity of insulin action.

7 tricularly mediated blockade of hypothalamic insulin action.

8 atic ATGL on mediating glucose tolerance and insulin action.

9 of TXNIP, a well-known negative regulator of insulin action.

10 ytokine as both an enhancer and inhibitor of insulin action.

11 -chain fatty acid oxidation disrupts hepatic insulin action.

12 substantially impairs glucose tolerance and insulin action.

13 taining the balance between inflammation and insulin action.

14 hesis of lipotoxic ceramides that antagonize insulin action.

15 umulation yet paradoxically improves hepatic insulin action.

16 s related to reduced insulin sensitivity and insulin action.

17 ved in vivo monitoring of glucocorticoid and insulin action.

18 4 to cell cortex landing zones important for insulin action.

19 of rictor and mTOR, thereby down-regulating insulin action.

20 ycerol, ceramide, and acylcarnitine, disrupt insulin action.

21 ole in regulating hepatic and adipose tissue insulin action.

22 nd is critical for maintenance of whole body insulin action.

23 g with assessment of substrate selection and insulin action.

24 and suggest a more complex role for DAGs in insulin action.

25 eta-cell proliferation and if they influence insulin action.

26 ons, including modulation of skeletal muscle insulin action.

27 ype 2 diabetes results from an impairment of insulin action.

28 cose-lowering activity results from enhanced insulin action.

29 enesis and controls adipocyte metabolism and insulin action.

30 ulin sensitivity but also in skeletal muscle insulin action.

31 n (PST), has been reported to interfere with insulin action.

32 ons in regulating hepatic and adipose tissue insulin action.

33 s by altering either hepatic or extrahepatic insulin action.

34 ciates with both IR and IRS-1 and influences insulin action.

35 sma membrane of adipocytes is a key facet of insulin action.

36 FoxO proteins are major targets of insulin action.

37 forms (IRB and IRA) that are responsible for insulin action.

38 and muscle tissues) and is rate limiting in insulin action.

39 delivery and largely independent of hepatic insulin action.

40 tributes to exercise-induced improvements in insulin action.

41 normal function of white adipose tissue and insulin action.

42 es that the brain is an important target for insulin action.

43 cts increased, consistent with physiological insulin actions.

44 Hyperglycemia and reduced insulin actions affect many biological processes.

45 l fat do not seem to explain improvements in insulin action after RYGB in the Zucker rat model.

46 by expression of the paralogous gene Bmal2, insulin action and activity patterns are restored.

47 gh of insulin action and lack rhythmicity in insulin action and activity patterns.

48 The effect of pericentrin knockdown on insulin action and adipogenesis in 3T3-L1 adipocytes was

49 involved in the pathogenesis of T2DM, namely insulin action and beta cell function, and is considered

50 ence beta-cell physiology through regulating insulin action and demonstrated the therapeutic potentia

51 rous documentation for a circadian rhythm of insulin action and demonstrates that disturbing the natu

52 (9,39), but not GLP-1-(9,36)amide, decreases insulin action and DI in healthy humans.

53 tivator of transcription 6 (STAT6) decreases insulin action and enhances a peroxisome proliferator-ac

54 -induced visceral obesity but also regulates insulin action and glucose homeostasis, independently of

55 tion and autophagy and, remarkably, improves insulin action and glucose homeostasis.

56 Amino acids profoundly affect insulin action and glucose metabolism in mammals.

57 type 2 diabetes is characterized by impaired insulin action and increased hepatic glucose production

58 Conversely, Ctrp6 gene deletion improved insulin action and increased metabolic rate and energy e

59 Smoking decreases insulin action and increases the risk of type 2 diabetes

60 and LRP5 activity can serve as modifiers of insulin action and insulin resistance in the pathophysio

61 TRA6 is necessary for diurnal rhythmicity of insulin action and JAK/STAT signaling in adipose tissue.

62 -knockout mice are locked into the trough of insulin action and lack rhythmicity in insulin action an

63 hereas its muscle-specific ablation impaired insulin action and led to postprandial glucose intoleran

64 l fat depletion, have succeeded in improving insulin action and life span in rodents.

65 ivity have the potential to improve systemic insulin action and limit weight gain on an obesigenic di

66 nction declines with aging, which can reduce insulin action and may contribute to increased risk of t

67 ne the effect of TUDCA therapy on multiorgan insulin action and metabolic factors associated with ins

68 he c-Jun N-terminal kinase (JNK) to regulate insulin action and metabolism.

69 lish the molecular link between dysregulated insulin action and mitochondrial function.

70 /lysosomal trafficking system may coordinate insulin action and nutrient homeostasis by endocytosis o

71 c dyslipidemia and the worsening of impaired insulin action and obesity.

72 for compounds that enhance and partly mimic insulin action and replicate some effects of bariatric s

73 eveal a new role of MAM integrity in hepatic insulin action and resistance, providing a novel target

74 ented exercise training increased whole-body insulin action and reversed impairments in AS160 phospho

75 tivation and downstream signaling leading to insulin action and secretion.

76 minished in vivo cardiac and skeletal muscle insulin action and signaling.

77 exercise training could rescue decrements in insulin action and skeletal muscle AS160 phosphorylation

78 muscle is a critical regulator of leptin and insulin action and that increased SOCS may mediate insul

79 cate that FoxO1 proteins negatively regulate insulin action and that their effect may be explained, a

80 The effect of fenretinide on insulin action and the cellular lipidome was assessed in

81 -kinase (PI3K) p110alpha plays a key role in insulin action and tumorigenesis.

82 analyzed to assess the role of this gene in insulin action and type 2 diabetes.

83 Nevertheless, muscle insulin action and vascularity were increased.

84 d risk for diabetes decreased in response to insulin action and were elevated in the setting of insul

85 via the portal vein is important for hepatic insulin action and, therefore, presumably for hepatic in

86 and DAG in skeletal muscle may be related to insulin action, and 3) basal inhibition of insulin recep

87 es included lipid and fatty acid metabolism, insulin action, and cell-cycle regulation.

88 TBC1D1(-/-) mice and analyzing body weight, insulin action, and exercise.

89 -cell function and beta-cell mass, normalise insulin action, and fully correct glucose homoeostasis a

90 presence of altered eNOS activation, reduced insulin action, and inflammatory activation in the endot

91 Regular exercise training improves insulin action, and is a primary treatment modality for

92 that Shp2 is a negative regulator of hepatic insulin action, and its deletion enhances the activation

93 etween the PI3K pathway, which is central to insulin action, and the regulation of the cellular respo

94 fied loci affect both beta-cell function and insulin action, and, overall, T2D association signals sh

95 uscle causes an increase, not a decrease, in insulin action; and 3) most of the studies comparing fat

96 bnormalities in hepatic lipid metabolism and insulin action are believed to play a critical role in t

97 es insulin signaling, but its effects on CNS insulin action are largely unknown.

98 findings indicate that localized changes in insulin action are responsible for the differential phos

99 le for rs1570056 was associated with reduced insulin action as assessed by either HOMA-IR in 2,549 no

100 n adipocytes, monocytes, and hepatocytes for insulin action-associated loci.

101 glucose uptake was independent of defects in insulin action at the myocyte, suggesting that the impai

102 and muscle-specific glucose homeostasis and insulin action based on glucose and insulin tolerance te

103 rons (AgRP IR KO) exhibited impaired hepatic insulin action because the ability of insulin to suppres

104 drenergic receptor agonist, which sensitizes insulin action but has no direct effect on the mouse mam

105 cription factor, is an important mediator of insulin action, but its role in the regulation of lipid

106 ion, which is at least partially mediated by insulin action, but not GABA-A receptors.

107 E3 ubiquitin ligase MARCH1 impairs cellular insulin action by degrading cell surface INSR.

108 phatase 1B (PTP1B) is postulated to modulate insulin action by dephosphorylating the insulin receptor

109 GLP-1 may afford potential to improve muscle insulin action by expanding microvascular endothelial su

110 sia dracunculus L. (termed PMI5011) improves insulin action by increasing insulin signaling in skelet

111 ersely, activation of STAT6 by IL-4 improves insulin action by inhibiting the PPARalpha-regulated pro

112 that pharmacological FFA reduction enhances insulin action by reducing local (muscle) inflammation,

113 ose significantly enhances the assessment of insulin action by segregating insulin sensitivity into i

114 esonance spectroscopy were used to determine insulin action, cellular insulin signaling, and intrahep

115 Thus, central and peripheral insulin action combined to control some, but not other,

116 ce became markedly obese but showed improved insulin action compared to that of wild-type mice, which

117 This beneficial effect on insulin action could be related to a decrease in local i

118 Improvement of hypothalamic insulin action decreases fasting glycemia, glycemia afte

119 dipocytes on myocyte substrate selection and insulin action depended on the metabolic state of the sy

120 Surprisingly, insulin action determined by HI clamps did not differ be

121 How this occurs and whether uncoupled insulin action develops in other tissues is unknown.

122 Nevertheless, inhibition of hypothalamic insulin action did not alter the effects of the hormone

123 T cell homeostasis regulate inflammation and insulin-action during obesity?

124 ose utilization and uncouples impairments in insulin action from hepatic TAG accumulation.

125 espite this, the role of SphK1 in regulating insulin action has been largely overlooked.

126 tween the metabolomic amino acid profile and insulin action (i.e., glucose disposal rate [GDR]).

127 e recently demonstrated a diurnal pattern to insulin action (i.e., insulin sensitivity [SI]) in healt

128 tion on parameters of glucose metabolism and insulin action in a dietary mouse model of obesity.

129 Identification of uncoupled insulin action in adipocytes suggests this condition mig

130 icentrin deficiency does not impair proximal insulin action in adipocytes.

131 stablishing that GIP has a general effect on insulin action in adipocytes.

132 novel signal transduction pathway modulating insulin action in adipocytes.

133 simulated scenarios and applied it to study insulin action in adipocytes.

134 during hyperinsulinemia, suggesting impaired insulin action in adipose tissue, whereas no association

135 s associated with hyperglycemia and impaired insulin action in adipose tissue.

136 Restoration of insulin action in AgRP neurons normalized insulin suppre

137 Fetuin-A interferes with insulin action in animal studies, but data on fetuin-A a

138 ither WIN or ACEA infusions acutely impaired insulin action in both liver and adipose tissue.

139 llitus (DM2) affect contractile function and insulin action in cardiomyocytes.

140 e that in addition to prosurvival signaling, insulin action in early life mediates the physiological

141 Insulin action in endothelial cells and femoral artery f

142 maximal life span, and consistently increase insulin action in experimental animals.

143 , and phosphatidic acid (PA), which inhibits insulin action in hepatocytes by disrupting the assembly

144 generation of nitric oxide (NO) that impairs insulin action in hepatocytes via tyrosine nitration of

145 e in GIRs was associated with regional brain insulin action in hypothalamus and striatum.

146 suggests that chronic hyperglycemia impairs insulin action in individuals with type 2 diabetes.

147 eceptor (CB1R) agonism/antagonism influences insulin action in insulin-sensitive tissues.

148 cer development, we examined tissue-specific insulin action in intestinal tumour formation.

149 w that hepatic ILK deletion has no effect on insulin action in lean mice but sensitizes the liver to

150 duction and inflammation and enhances tissue insulin action in lean rats and 2) prevents muscle metab

151 perinsulinemic-euglycemic clamps, we studied insulin action in Liv-DGAT2 mice and their wild-type (WT

152 in mediating GLUT4 trafficking and therefore insulin action in mice.

153 PA, but not DAG, is associated with impaired insulin action in mouse hepatocytes.

154 Resistin antagonizes insulin action in mouse, making it a potential therapeut

155 nsulinemia, hepatic steatosis and diminished insulin action in muscle and adipose tissues.

156 calcium deposition in the vasculature and of insulin action in muscle and fat, and may be involved in

157 d FA are powerful and opposite regulators of insulin action in muscle.

158 e plays a critical role in the regulation of insulin action in muscle.

159 tment has weight loss-independent effects on insulin action in obese subjects with type 2 diabetes.

160 unities in targeting early defects in muscle insulin action in order to counteract the development of

161 ncy, but it is not known whether it improves insulin action in people who are not leptin deficient.

162 ulates the kinetics of insulin signaling and insulin action in peripheral target tissues and differen

163 Impaired insulin action in peripheral tissues is a major pathogen

164 r glucosylceramide derivatives, which impair insulin action in peripheral tissues.

165 lating kinase 1 (ASK1) may influence in vivo insulin action in Pima Indians.

166 Abrogating insulin action in POMC neurons of the offspring prevents

167 lle contacts by overexpressing CypD enhanced insulin action in primary hepatocytes of diabetic mice.

168 e that can alter insulin clearance and hence insulin action in response to blood glucose, mitigating

169 nism whereby a high fat/sucrose diet impairs insulin action in retina.

170 d the repressive effect of JNK activation on insulin action in retinas.

171 production and inflammation while enhancing insulin action in rodent skeletal muscle.

172 mportant regulator of lipid partitioning and insulin action in skeletal muscle under conditions of in

173 alpha positively mediates glucose uptake and insulin action in skeletal muscle.

174 lpha is important for glucose metabolism and insulin action in skeletal muscle.

175 Inadequate insulin action in skeletal myocytes contributes to hyper

176 rget of muscle glucose sensing that augments insulin action in skeletal myocytes.

177 d turnover are not related to alterations in insulin action in smokers compared to nonsmokers, 2) inc

178 of insulin receptor substrate-1 may decrease insulin action in smokers.

179 e in insulin sensitivity, including impaired insulin action in suppressing lipolysis and lipid oxidat

180 Thus, alterations in insulin action in the brain can contribute to metabolic

181 Animal studies suggest that insulin action in the brain is involved in the regulatio

182 Disruption of insulin action in the brain leads to impairment of neuro

183 about the overall physiological relevance of insulin action in the brain on hepatic glucose metabolis

184 Together, dietary intake of MUFAs promoted insulin action in the brain with its beneficial effects

185 ects have been postulated to be mediated via insulin action in the brain, although peripheral effects

186 the coordination of fatty acid oxidation and insulin action in the fasting-refeeding transition.

187 Improved muscle insulin action in the HF-fed ILK(lox/lox)HSAcre mice was

188 erglycemia in diabetic mice independently of insulin action in the liver by increasing energy metabol

189 Thus, we assessed the role of central insulin action in the response of the liver to normal ph

190 r intestinal tumour cells in vitro, impaired insulin action in the tumour microenvironment may be mor

191 tablish a novel role for PTP1B in regulating insulin action in the VMH and suggest that increased ins

192 target tissues; however, how this impacts on insulin action in vivo is unclear.

193 To determine the role of ILK in hepatic insulin action in vivo, male C57BL/6J ILK(lox/lox) mice

194 HI) clamps were performed to assess GSIS and insulin action in vivo.

195 tissues have been implicated in attenuating insulin action in vivo.

196 nd obesity-induced down-regulation of IR and insulin action in vivo.

197 idative stress is not a major determinant of insulin action in vivo.

198 of T cells from epididymal fat pads improved insulin action in young DIO mice but did not reverse obe

199 ovides evidence to support the importance of insulin actions in preventing cardiovascular pathology t

200 To delineate insulin actions in the brain, neuron-specific insulin re

201 e regulation with robust effects on cellular insulin action, in vivo insulin sensitivity, and overall

202 elevated cellular stress as well as impaired insulin action, increased glucose production and lipid d

203 The contribution of altered myocardial insulin action, independent of associated changes in sys

204 n linked to lipid and membrane biosynthesis, insulin action, inflammation, and apoptosis.

205 unctionally link TUSC5 to GLUT4 trafficking, insulin action, insulin resistance, and PPARgamma action

206 t a selective postreceptor defect in hepatic insulin action is central to the pathogenesis of fatty l

207 It has long been appreciated that insulin action is closely tied to circadian rhythms.

208 erving muscle mass under conditions in which insulin action is deficient.

209 Insulin action is mediated via insulin receptors (IR) re

210 mitochondrial performance, lipotoxicity, and insulin action is more complex than previously proposed.

211 These data indicate that brain insulin action is not a determinant of the rapid (<4 h)

212 le clinical observations have suggested that insulin action is not constant throughout the 24 hr cycl

213 and browning of white fat, but intact liver insulin action is required for FGF21 to control hepatic

214 SP2), a protein previously unassociated with insulin action, is responsive to insulin stimulation.

215 Unlike insulin action, it was not associated with stimulation o

216 Enhanced AIR improved peripheral insulin action, leading to more rapid muscle glucose upt

217 e delivery, there was reduced sensitivity to insulin action measured by insulin tolerance test.

218 ble to diet-induced glucose intolerance, and insulin action measured in isolated skeletal muscles rem

219 on and their relationship with biomarkers of insulin action, metabolomic profiling was carried out in

220 amps to show a bona fide circadian rhythm of insulin action; mice are most resistant to insulin durin

221 O1, a key transcription factor that mediates insulin action on gene expression.

222 rosine phosphatase Shp1 negatively regulates insulin action on glucose homeostasis in liver and muscl

223 d CRY1 degradation as an important target of insulin action on glucose homeostasis.

224 ay-selective insulin resistance by promoting insulin action on glucose metabolism but limiting hepati

225 Hyperglycemia is a result of impaired insulin action on glucose production and disposal, and a

226 n L6 myocytes and FAO hepatic cells improved insulin action on glucose uptake and glucose production,

227 perturbations are associated with failure of insulin action on GLUT4 traffic to the cell surface and

228 bility of forkhead box O6 (FoxO6) to mediate insulin action on hepatic gluconeogenesis and its contri

229 ain endothelial function but also to mediate insulin action on peripheral glucose disposal.

230 human brain, we studied the impacts of brain insulin action on whole-body insulin sensitivity and the

231 Insulin actions on the vascular cells are mediated by tw

232 etic variation at the TCF7L2 locus may alter insulin action or directly modify hepatic glucose metabo

233 mic clamp experiments, NTE-1 did not enhance insulin action or increase plasma insulin levels.

234 Z-treated Gcgr(-/-) animals requires remnant insulin action originating from spared residual beta-cel

235 sion in skeletal muscle biopsies and in vivo insulin action (P = 0.02, r = 0.23), and the risk allele

236 uvant therapy in diabetes only when residual insulin action persists, and ii) help devising future be

237 de in skeletal muscle linking CR to improved insulin action, primarily via modulation of PI3K signali

238 In rodents, acute brain insulin action reduces blood glucose levels by suppressi

239 dependent pathway, it is unknown whether DVC insulin action regulates food intake.

240 ecule of insulin-like growth factor 1 (IGF1)/insulin actions, regulates Runx2 activity and expression

241 ithin skeletal muscle linking CR to improved insulin action remain largely unknown.

242 ne system regulates nutrient homeostasis and insulin action remain poorly understood.

243 her factors beyond glucose effectiveness and insulin action require consideration.

244 Insulin action required PI3K and Akt, which suppress Fox

245 Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be

246 issue lipolysis, and impaired adipose tissue insulin action results in unrestrained lipolysis and lip

247 nd cardiorespiratory fitness and measures of insulin action (secondary measurements).

248 The simultaneous assessment of insulin action, secretion, and hepatic extraction is key

249 Prolonging insulin action selectively in the mature adipocyte is th

250 le for the renal nerves in the regulation of insulin action specifically at the level of the liver an

251 glucose uptake, and this was due to impaired insulin action specifically in skeletal muscle.

252 The mechanism by which CR enhances insulin action, specifically in higher species, is not p

253 retion along with the established effects on insulin action suggest potential for HN and its analogs

254 d inflammatory pathways to the antagonism of insulin action that contributes to diabetes.

255 at Irs1 is the principal mediator of hepatic insulin action that maintains glucose homeostasis.

256 ctors and widespread downstream effectors of insulin actions that influence both reproductive and non

257 itioning of RTKs in target cells for EGF and insulin action, the temporal extent of signaling, attenu

258 In addition to identifying a novel mode of insulin action, these data raise the possibility of deve

259 d IRS-1 phosphorylation by p70S6K1 attenuate insulin action through a negative feedback pathway.

260 reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fu

261 alpha-mediated hypoxic signaling and hepatic insulin action through Irs2 induction, which can be co-o

262 Is as inhibitors of IRS protein function and insulin action through the activation of GSK3beta.

263 benefit to enhance mitochondrial quality and insulin action to ameliorate complications associated wi

264 during a clamp, reaffirming that the site of insulin action to control EGP is extrahepatic.

265 dentifies specific contributions of impaired insulin action to mitochondrial dysfunction in the heart

266 uch as that seen during obesity, may inhibit insulin action to muscle cells and exacerbate insulin re

267 The importance of hypothalamic insulin action to the regulation of hepatic glucose meta

268 ined the effects of pericentrin depletion on insulin action using 3T3-L1 adipocytes as a model system

269 Insulin action was enhanced after isomaltulose compared

270 Under this condition, insulin action was enhanced in myotubes from lean but no

271 Insulin action was evaluated in the various models by me

272 ; activation of glucokinase was restored and insulin action was improved, stimulating muscle glucose

273 However, insulin action was lowered by exendin-(9,39) (25 +/- 4 v

274 Insulin action was measured by a three-stage hyperinsuli

275 Insulin action was normal in liver but compromised in sk

276 in sensitivity compared with sedentary mice, insulin action was not affected by AraC administration.

277 Insulin action was not impaired in the lean SIRT3 KO mic

278 Insulin action was studied in the presence or absence of

279 Since insulin action was unaffected, we hypothesized that the

280 Contractile function and insulin action were analyzed in primary adult rat cardio

281 on, hepatic fatty acid oxidation and hepatic insulin action were assessed in vitro using primary hepa

282 Both the molecular and metabolic aspects of insulin action were assessed.

283 Decrements in whole-body insulin action were associated with impairments in insul

284 These adaptations in skeletal muscle insulin action were completely abrogated in mice lacking

285 Notably, the improvements in insulin action were more pronounced in T2DM, indicating

286 Reduced oxygen consumption and impaired insulin action were recapitulated in Parkin-null myotube

287 therefore propose a new model for CLASP2 in insulin action, where CLASP2 directs the delivery of GLU

288 receptor inactivation in ECs does not impair insulin action, whereas inactivation of Irs2 does.

289 h targeting the extramyocellular barriers to insulin action, which are critical to the pathogenesis o

290 ue (AT) inflammation contributes to impaired insulin action, which is a major cause of type 2 diabete

291 In summary, overfeeding impairs hypothalamic insulin action, which may contribute to unrestrained lip

292 r integrin signaling in facilitating hepatic insulin action while promoting lipid accumulation in mic

293 ectin secretion but not adipsin secretion or insulin action, while in preadipocytes it impaired adipo

294 cose-stimulated insulin secretion (GSIS) and insulin action, wild-type (sod2(+/+)) and heterozygous k

295 s that disturbing the natural rhythmicity of insulin action will disrupt the rhythmic internal enviro

296 severely disrupted, it is not known whether insulin action will lock to the peak, nadir, or mean of

297 substrate and hence integrates nutrients and insulin action with a defined pathogen response system.

298 ruitment using contrast-enhanced ultrasound, insulin action with euglycaemic hyperinsulinaemic clamp,

299 Lipid metabolism is important for health and insulin action, yet the fundamental process of regulatin

300 (PMI 5011) improves insulin action, yet the precise mechanism is not known.